CA2924535A1 - Nanoparticle-mediated gene delivery, genomic editing and ligand-targete d modification in various cell populations - Google Patents

Nanoparticle-mediated gene delivery, genomic editing and ligand-targete d modification in various cell populations Download PDF

Info

Publication number
CA2924535A1
CA2924535A1 CA2924535A CA2924535A CA2924535A1 CA 2924535 A1 CA2924535 A1 CA 2924535A1 CA 2924535 A CA2924535 A CA 2924535A CA 2924535 A CA2924535 A CA 2924535A CA 2924535 A1 CA2924535 A1 CA 2924535A1
Authority
CA
Canada
Prior art keywords
nanoparticle
polymer
poly
cationic
polyplex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2924535A
Other languages
French (fr)
Other versions
CA2924535C (en
Inventor
Shiva Prasad KOTHA
Andre Ronald WATSON
Vaibhav A. PANDIT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rensselaer Polytechnic Institute
Original Assignee
Rensselaer Polytechnic Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rensselaer Polytechnic Institute filed Critical Rensselaer Polytechnic Institute
Priority to CA3175320A priority Critical patent/CA3175320A1/en
Publication of CA2924535A1 publication Critical patent/CA2924535A1/en
Application granted granted Critical
Publication of CA2924535C publication Critical patent/CA2924535C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/95—Protection of vectors from inactivation by agents such as antibodies or enzymes, e.g. using polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Toxicology (AREA)

Abstract

An improved nanoparticle for transfecting cells is provided. The nanoparticle includes a core polyplex and a silica coating on the core polyplex and, optionally, a polymer attached to an outer surface of the silica coating, where the polyplex includes an anionic polymer, a cationic polymer, a cationic polypeptide, and a polynucleotide. Also provided is an improved method of modifying intracellular polynucleotides. The method includes contacting a cell with a nanoparticle that includes a core polyplex and a silica coating on the core polyplex and, optionally, a polymer attached to an outer surface of the silica coating, where the polyplex includes an anionic polymer, a cationic polymer, a cationic polypeptide, and a polynucleotide.

Description

NANOPARTICLE-MEDIATED GENE DELIVERY, GENOMIC
EDITING AND LIGAND-TARGETED MODIFICATION IN
VARIOUS CELL POPULATIONS
Cross-Reference to Related Applications [0001] This application claims priority under 35 U.S.C. 119 to U.S.
Provisional Application No. 61/881,072, filed September 23, 2013, which is herein incorporated by reference in its entirety.
Government Rights Statement
[0002] This invention was made with U.S. Government support under RO1 AG030637 awarded by the National Institutes of Health. The U.S. Government has certain rights in the invention.
BACKGROUND OF THE INVENTION
Technical Field
[0003] The present invention generally relates to use of nanoparticles to transfect cells. More particularly, the present invention relates to coated nanoparticles with a polyplex core for intracellular delivery of ploynucleotides to modify gene expression.
Background Information
[0004] Introducing polynucleotides into cells to alter gene expression requires appropriate packaging of the polynucleotides to protect them from degradation before cell entry, to permit entry into cells, and to direct delivery to the appropriate subcellular compartment. Effectiveness in altering expression may also depend on time-frames of release of polynucleotides from packaging after cellular entry.
Available nanoparticle-based technologies for modifying gene expression suffer from low levels of cellular transfection and limited effectiveness upon transfection, at least in part because of their limitations in satisfying the foregoing requirements.
It is therefore desirable to obtain a nanoparticle-based transfection agent and method of use thereof that addresses all of these requirements to enhance effectiveness.
5 SUMMARY OF THE INVENTION
[0005] The shortcomings of the prior art are overcome, and additional advantages are provided, through the provision, in one aspect, of a nanoparticle. The nanoparticle includes a core polyplex and a silica coating on the core polyplex, and the polyplex includes an anionic polymer, a cationic polymer, a cationic polypeptide, and a polynucleotide. In another aspect, the nanoparticle may also include a polymer attached to an outer surface of the silica coating.
[0006] A method of modifying intracellular polynucleotides is also provided.
The method includes contacting a cell with a nanoparticle that includes a core polyplex and a silica coating on the core polyplex, and the polyplex includes an anionic polymer, a cationic polymer, a cationic polypeptide, and a polynucleotide. In another aspect, the nanoparticle may also include a polymer attached to an outer surface of the silica coating.
[0007] Additional features and advantages are realized through the techniques of the present invention. These, and other objects, features and advantages of this invention will become apparent from the following detailed description of the various aspects of the invention taken in conjunction with the accompanying drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
[0008] One or more aspects of the present invention are particularly pointed out and distinctly claimed as examples in the claims at the conclusion of the specification.
The foregoing and other objects, features, and advantages of the invention are apparent from the following detailed description taken in conjunction with the accompanying drawings in which:
[0009] FIGs. 1A-1B are diagrammatic representations of some embodiments of a nanoparticle and components thereof in accordance with an aspect of the present invention;
[0010] FIGs. 2A is a diagrammatic representation of how a nanoparticle may be manufactured in accordance with an aspect of the present invention;
[0011] FIG. 2B is a diagrammatic representation of means by which a cell may uptake and intracellularly process a nanoparticle in accordance with an aspect of the present invention;
[0012] FIG. 3 is a graph illustrating the effects on polyplex complexation of including different ratios of various charged polymers and polynucleotides in accordance with an aspect of the present invention;
[0013] FIG. 4 is a graph illustrating the effects on polyplex complexation of including different ratios of various charged polymers and polynucleotides, with or without including an anionic polymer in the polyplex, in accordance with an aspect of the present invention;
[0014] FIG. 5 is a graph illustrating the destabilizing effect on a polyplex of including increasing amounts of an anionic polymer in the presence or absence of cationic polypeptides in accordance with an aspect of the present invention;
[0015] FIG. 6 is a graph illustrating sizes of nanoparticles possessing various layers in accordance with an aspect of the present invention;
[0016] FIG. 7 is photomicrographs of cells transfected with various nanoparticles demonstrating cellular uptake and subcellular localization of nanoparticles following transfection in accordance with an aspect of the present invention;
[0017] FIG. 8 is photomicrographs of cells transfected with nanoparticles showing duration of residence of nanoparticles in cells following transfection in accordance with an aspect of the present invention;
[0018] FIGs. 9A-B is photomicrographs showing cellular uptake of nanoparticles possessing a layer of polymers attached to the outside of a silica coating of a polyplex in accordance with an aspect of the present invention;
[0019] FIG. 10 is a diagrammatic representation of TALEN peptides encoded for by a nucleic acid included in a nanoparticle that cause knockdown of expression of sclerostin in accordance with an aspect of the present invention;
[0020] FIGs. 11A-11C are graphs illustrating the effects transfecting cells with different amounts of nanoparticles that target sclerostin expression on sclerostin and I3-catenin expression in accordance with an aspect of the present invention;
[0021] FIGs. 12A-12F are graphs illustrating the effects of transfecting cells with different amounts of nanoparticles that target sclerostin expression on expression levels of various cellular signaling peptides in accordance with an aspect of the present invention;
[0022] FIG. 13 is photomicrographs demonstrating effects of transfecting cells with nanoparticles that target sclerostin expression on expression of a co-transfected reporter gene that is responsive to transcription factors whose activity is inhibited by sclerostin-mediated signalling in accordance with an aspect of the present invention;
[0023] FIGs. 14A-14C are photomicrographs demonstrating effects of transfecting cells with nanoparticles that target sclerostin expression on mineralization in accordance with an aspect of the present invention.
DETAILED DESCRIPTION OF THE INVENTION
[0024] Aspects of the present invention and certain features, advantages, and details thereof, are explained more fully below with reference to the non-limiting embodiments illustrated in the accompanying drawings. Descriptions of well-known materials, fabrication tools, processing techniques, etc., are omitted so as to not unnecessarily obscure the invention in detail. It should be understood, however, that the detailed description and the specific examples, while indicating embodiments of the invention, are given by way of illustration only, and are not by way of limitation.
Various substitutions, modifications, additions and/or arrangements within the spirit and/or scope of the underlying inventive concepts will be apparent to those skilled in the art from this disclosure.
[0025] The present disclosure provides, in part, a multilayered nanoparticle for transfecting cells with agents to modify gene expression. Nanoparticles designed for improved serum stability, targetted delivery to specific cell types, greater nuclear specificity and compartment-specific unpackaging, improved ability to retain significant payload levels during initial stages of internalization, and ability to maintain release of payload for a various durations following internalization, and methods of use thereof, are provided.
[0026] In one aspect, complexes of polynucleotides with polymers, or polyplexes, created by condensation of cationic polymers and polynucleotides in the presence of anionic polymers may mediate increased transfection efficiency over polynucleotide-cationic polymer conjugates. Though this process may produce more particles and increase the net surface area of nanoparticles exposed for cellular uptake, an improved electrostatic repulsory element may also be at play in releasing nucleic acids through this technique. Surprisingly, in contrast to a more rapid disaggregation of nucleotides from nanoparticle polyplexes that include anionic polymers as would have been predicted on the basis of existing literature, in one aspect of the present invention, including an anionic polymer in a nanoparticle polyplex core may prolong the duration of intracellular residence of the nanoparticle and release of agents that affect gene expression or otherwise regulate cellular function, or payloads.
[0027] In another aspect, the presence of a cationic polypeptide in a nanoparticle may mediate stability, subcellular compartmentalization, and payload release.
As one example, fragments of the N-terminus of histone peptides, referred to generally as histone tail peptides, within various polyplexes are not only capable of being deprotonated by various histone modifications, such as in the case of histone acetyltransferase-mediated acetylation, but may also mediate effective nuclear-specific unpackaging as components of polyplexes. Their trafficking may be reliant on alternative endocytotic pathways utilizing retrograde transport through the Golgi and endoplasmic reticulum, and the nature of histones existing inside of the nuclear envelope suggests an innate nuclear localization sequence on histone tail peptides. In one aspect of the present invention, including a histone tail peptide may promote nuclear localization of nanoparticles and result in enzyme-mediated release of polynucleotide payload therefrom.
[0028] In another aspect, silica coatings of polyplexes may seal their payloads before and during initial cellular uptake. Commonly used polyplexes consisting of poly(ethylenimine) and DNA have a tendency to shed the majority (¨ 90%) of their payloads during cellular internalization, with the remaining payload often remaining bound to its cationic nanocarrier's polymeric remains. With transiently stabilizing interlayers of silica, greater intracellular delivery efficiency may be observed despite decreased probability of cellular uptake. In another aspect of the present invention, coating a nanoparticle polyplex with a silica coating may seal the polyplex, stablizing it until its release upon processing in the intended subcellular compartment.
[0029] In another aspect of the present invention, transfection efficiency may be further increased by adding another layer of cationic polymer, making the delivery efficiency as much as two orders of magnitude greater than a bare or silica-coated polyplex, presumably due to the anionic nature of an oligomeric silica coating being cell repulsive. In a further aspect, silica-coated polyplexes and their further-layered derivatives are stable in serum and are suitable for in vivo experiments unlike cationic polymer/nucleic acid conjugates on their own.
[0030] FIGs. 1A-1B show examples of components of a nanoparticle in accordance with the present invention. In accordance with the present invention, a nanoparticle polyplex core may include a polynucleotide, an anionic polymer, a cationic polymer, and a cationic polypeptide. A silica coating may then be applied to the polyplex core, and polymers may then be attached to an outer surface of the silica coating.
The polynucleotide may be a DNA vector for driving intracellular expression of a nucleic acid sequence it contains. However, a nanoparticle may also comprise other types of polynucleotides, such as linear DNA or various types of RNA, including dsDNA, ssDNA, mRNA, siRNA, or CRISPR RNA sequences, or others, or any combination of the foregoing. A nanoparticle may also include, in addition to or in place of any of the foregoing examples of polynucleotides, a peptide nucleic acid, other charged or polar small molecules between 50 and 1000 Da, or alternatively between 200 and kDa, in size, such as cyclic nucleotides such as cAMP, DNA origami templates, aptamers, charged polypeptides, proteins or protein fragments between 2 and kDa, peptoids, phosphorylated or sulfated constituents, anionically modified constituents, and multimeric or oligomeric combinations of the foregoing. A
person of ordinary skill would understand any of the foregoing, or any combination thereof, as being included within the present invention.
[0031] Continuing with FIG 1A, in one aspect of the invention, a cationic polymer within the polyplex may be a polypeptide containing cationic amino acids and may be, for example, poly(arginine), poly(lysine), poly(histidine), poly(ornithine), poly(citrulline), or a polypeptide that comprises any combination of more than one of the foregoing. A nanoparticle may also include, in addition to or in place of any of the foregoing examples of cationic polymers, poly(ethylenimine), poly(aspartamide), polypeptoids, a charge-functionalized polyester, a cationic polysaccharide, an acetylated amino sugar, chitosan, or a variant or variants that comprise any combination of more than one of the foregoing, in linear or branched forms.
[0032] In one example, a cationic polymer may comprise a poly(arginine), such as poly(L-arginine). A cationic polymer within the polyplex may have a molecular weight of between 1 kDa and 200 kDa. A cationic polymer within the polyplex may also have a molecular weight of between 10 kDa and 100 kDa. A cationic polymer within the polyplex may also have a molecular weight of between 15 kDa and 50 kDa.
In one example, a cationic polymer comprises poly(L-arginine) with a molecular weight of approximately 29 kDa, as represented by SEQ ID NO: 1 (PLR). In another example, a cationic polymer may comprise linear poly(ethylenimine) with a molecular weight of 25 kDa (PEI). In another example, a cationic polymer may comprise branched poly(ethylenimine) with molecular weight of 10 kDa. In another example, a cationic polymer may comprise branched poly(ethylenimine) with a molecular weight of 70 kDa. In another example, a cationic polymer may comprise a D-isomer of poly(arginine) or of any of the foregoing polymers such as polypeptides, which may be particularly advantageous because polymers such as polypeptides containing a D-isomer may be less susceptible to degradation within a cell and therefore have a prolonged effect on influencing payload release and the rate thereof over time.
[0033] Continuing with FIG 1A, in a further aspect of the invention, an anionic polymer within the polyplex may be a polypeptide containing anionic amino acids, and may be, for example, poly-glutamic acid or poly-aspartic acid, or a polypeptide that comprises any combination of the foregoing. A nanoparticle may also include, in addition to or in place of any of the foregoing examples of anionic polymers, a glycosaminoglycan, a glycoprotein, a polysaccharide, poly(mannuronic acid), poly(guluronic acid), heparin, heparin sulfate, chondroitin, chondroitin sulfate, keratan, keratan sulfate, aggrecan, poly(glucosamine), or an anionic polymer that comprises any combination of the foregoing. In one example, an anionic polymer may comprise poly-glutamic acid. An anionic polymer within the polyplex may have a molecular weight of between 1 kDa and 200 kDa. An anionic polymer within the polyplex may also have a molecular weight of between 10 kDa and 100 kDa. An anionic polymer within the polyplex may also have a molecular weight of between 15 kDa and 50 kDa. In one example, an anionic polymer is poly(glutamic acid) with a molecular weight of approximately 15 kDa. Polymers consisting of or including a D-isomer of glutamic acid may be particularly advantageous because they may be less susceptible to degradation within a cell and therefore have a prolonged effect on influencing payload release and the rate thereof over time. For example, the anionic polymer within the polyplex may have the sequence represented by SEQ ID NO: 2 (PDGA). In another example, an anionic polymer may comprise a D-isomer of any of the foregoing polymers or polypeptides, which may be particularly advantageous because polymers such as polypeptides containing a D-isomer may be less susceptible to degradation within a cell and therefore have a prolonged effect on influencing payload release and the rate thereof over time.
Continuing with FIG. 1A, in another aspect of the invention, a cationic peptide in a nanoparticle's polyplex core may be a fragment of a histone peptide, such as of the H1, H2, H3, or H4 proteins. The fragment may include amino acids whose sequence corresponds to the N-terminus of a histone protein. For example, the fragment may comprise up to the first 5 (SEQ ID NO: 9), 10 (SEQ ID NO: 10), 15 (SEQ ID NO:
11), 20 (SEQ ID NO 12), 25 (SEQ ID NO: 13) or more N-terminal amino acids of a histone protein. The fragment may also be amidated on its C-terminus. The fragment may also have been modified such that one or more lysine residue is methylated, one or more histidine, lysine, arginine, or other complementary residues are acetylated or susceptible to acetylation as a histone acetyltransferase or acetyl CoA
substrate, or any combination of the foregoing. For example, a cationic peptide in a nanoparticle polyplex core may have the sequence as represented by SEQ ID NO: 3, which comprises the first 25 amino acids of the human histone 3 protein, amidated on its C-terminus, and tri-methylated on the lysine 4 in accordance with the present invention (HTP).
[0034] In another embodiment, a nanoparticle may include or contain, in addition to or in place of any of the foregoing cationic polypeptides, a nuclear localization sequence. A cationic polypeptide may comprise a nuclear localization sequence on its N- or C-terminus. A nuclear localization sequence may comprise an importin or karyopherin substrate, or may have or contain a sequence corresponding to SEQ
ID
NO: 8. In another embodiment, a nanoparticle may include, in addition to or in place of any of the foregoing cationic polypeptides, a mitochondrial localization signal or a peptide fragment of mtHSP70.
[0035] Continuing with FIG. 1B, in another aspect of the invention, the nanoparticle may comprise a reversible coating that provides stability to the polyplex core prior to cellular or compartmental internalization, preventing premature degradation or destabilization. For example, a silica coating may be applied to the polyplex core. In another example, calcium phosphate or hydroxyapatite may be applied to a polyplex core. In another example, a branched cationic polymer, polypeptide, or peptoid may be applied to a a polyplex core, with an anionic charge excess. A coating, such as a silica coating, may protect the polyplex from degradation before exposure to the endosomal microenvironment.
[0036] In another aspect, a nanoparticle may comprise a layer of polymers attached to or electrostatically bound with the external surface of coated polyplex, such as to or with the external surface of a silica coating. Such external polymers may serve to prevent cellular repulsion of the coated polyplex so as to promote contact with and uptake by a cell. An external polymer layer may also serve to promote internalization by specific cell types, such as if the externally attached polymer is or mimics a ligand to a receptor expressed by a cell type of which transfection is desired.
A polymer in a polymer layer attached to the outer surface of coating on a polyplex may be from between 0.1 to 20 kDa in size, or may be up to 40 or 50 kDa in size.
[0037] Examples of polymer comprising a polymer layer attached to the external surface of the coated core polyplex include those represented by SEQ ID NO: 4, which is an approximately 10 kDa poly(arginine) polymer, and SEQ ID NO: 5, which is human vasoactive endothelial growth factor protein, in accordance with the present invention. In another example, a polymer comprising a layer attached to the external surface of the coated core polyplex may comprise an anchor substrate of from between 1 to 25 repeating anionic or cationic moieties at the N-terminus, C-terminus, 5', or 3 end of a polymer, polypeptide, or polynucleotide to provide electrostatic conjugation of a targeting motif contained in the polymer, polypeptide, or polynucleotide to the coated polyplex core. In another example, a polymer comprising a layer attached to the external surface of the coated core polyplex may comprise a polymer, polypeptide, or polynucleotide sequence that exhibits base pair complementarity or binding affinity for an amino acid sequence binding motif to bind additional layers that may be added thereupon.
[0038] In another aspect of the present invention, illustrated in FIG. 2A, a cationic polyplex is created, then coated with a silica coating. Polyplex cores of nanoparticles may be created via electrostatic interactions leading to condensation. Two equal-volume solutions may be created, one with pH-unadjusted 40 mM HEPES (pH ¨5.5) combined with 0.1% w/v a cationic polymer and a cationic polypeptide in water and the other with 30 mM Tris-HC1 (pH ¨7.4) combined with 0.1% w/v anionic polymers and a polynucleotide in water. In one embodiment, the cationic polymer comprises SEQ ID NO: 1, the anionic polymer comprises SEQ ID NO: 2, and the cationic polypeptide comprises SEQ ID NO: 3. These solutions may be combined via dropwise addition of the cationic solution to the anionic one with no stirring. After 30 minutes of incubation at room temperature, a 200 uL solution containing 10 ug of nucleic acids within polyplexes may be added dropwise to a 45 mM sodium silicate (Sigma) solution in Tris-HC1 (pH = 7.4) and allowed to incubate for between 8 and 24 hours at room temperature. Silica-coated polyplexes may be isolated via centrifugation with a 300 kDa Nanosep0 filter (Pall, Port Washington, NY) at 3000g in order to isolate complexes from unbound silica species and polymers.
Nanoparticles may further be resuspended in a solution containing a polymer to be attached to the external surface of the silica coating. For example, they may be resuspended in a solution comprising a polymer represented by SEQ ID NO: 4 or SEQ ID NO: 5 at 0.1% w/v for one hour. Nanoparticles may then be centrifuged again before resuspension in transfection medium. This method is but one example of manufacturing nanoparticles in accordance with the present invention.
[0039] FIG. 2B is a diagrammatic representation of contacting a cell with a nanoparticle in accordance with the present invention leading to cellular internalization of the nanoparticle, such as by caveolae-mediated endocytosis or macropinocytosis. Nanoparticles may further be retrogradely transported through the Golgi and endoplasmic reticulum or processed through lysosomal pathways, resulting in loss of the coating, such as a silica coating, and exposure of the polyplex core. The polyplex core may further be translocated into the cell nucleus, where enzymatic processing my degrade the cationic polymer, such as through activity of arginases, or otherwise promote unpackaging of the polyplex core, such as through acetylation of a histone tail peptide within the polyplex, leading to release of polynucleotides such as plasmid DNA from the polyplex core, in accordance with the present invention.
Other intracellular processing steps modifying the constituents of a nanoparticle and its polyplex core or coating thereof or polymer layer attached to the coating may also occur in accordance with the present invention.
[0040] In a further aspect, the present invention includes optimized ratios of anionic and cationic polymers, cationic polypeptides, and polynucleotides for complexation of a polyplex core as part of a nanoparticle. In one example, plasmid DNA was fluorescently tagged with ethidium bromide (40 ng EtBr / ug DNA) before addition of various polymeric constituents in molar [1(positive)]:[1(negative)] ratios of [amine (n)]:[phosphate (p) + carboxylate (c)], or of c:p in the instance of poly(D-glutamic acid) (PDGA; SEQ ID NO: 2) addition. Addition of linear poly(ethylenimine) (PEI, 25 kDa) was compared to addition of poly(L-arginine) (PLR, 29 kDa; SEQ ID NO:
1) independently, as well as in conjunction with a H3K4(Me3) histone tail peptide (HTP;
SEQ ID NO: 3), in order to quantify similar complexation behaviors between the two polymers as part of a binary complex (i.e., PEI + DNA or PEI + DNA) or ternary complexes (HTP + PEI + DNA or HTP + PLR + DNA). Where a cationic polymer and cationic polypeptide were both present, the relative molar ratio of each component was 60%:40%, respectively. A Zeiss filter and spectrophotometer were used to excite EtBr-tagged DNA at 510 nm for an emission at 595 nm, and results were compared amongst various formulations with unbound EtBr as a negative control.
[0041] FIG. 3 is a graph showing the effects of varying the ratio of anionic or cationic polymers or polypeptides to polynucleotides. The X axis shows charged polymer-to-phosphate ratio and the Y axis shows relative fluorescence following combination of indicated constituents. A decrease in relative fluorescence indicates displacement of EtBr from DNA and polyplex formation. Ratios of cationic polymer, or of cationic polymer and cationic polypeptide, to DNA of approximately 5:1 and higher exhibited an approximately 40% decrease in fluorescence indicating complexation of DNA and polymers into polyplexes. Addition of PDGA in the absence of cationic polymers or cationic polypeptides did not affect complexation.
[0042] After complexing PLR-HTP-DNA, PEI-HTP-DNA, PLR-DNA and PEI-DNA polyplexes and determining that PDGA possesses no ability to cause complexation of polynucleotides, PDGA's influence on formation kinetics was established by comparison of [5.5(positive)]:[1(negative)] and [10(positive)]:[ 1 (negative)] molar ratios of [amine (n)]:[phosphate (p)] and [amine (n)]:[phosphate (p) + carboxylate (c)] on complexation efficiencies in order to determine effects of excess cationic and equalized charge ratios on nanoparticle complexation. Inclusion of carboxylate groups from PDGA was expected to have effects on overall formation kinetics comparable to inclusion of phosphate groups from DNA. Relative fluorescence was compared to DNA without addition of polymers or polypeptides or EtBr in the absence of DNA as controls.
[0043] FIG. 4 indicates the effects of adding PDGA to cationic polymers and cationic polypeptides on polyplex complexation kinetics. DNA was complexed with HTP, PLR or PEI, with or without addition of PDGA. Shown are experiments using cationic polymer (PLR or PEI)-to-polynucleotide molar ratios of 5.5:1 (as shown in the bars labeled nip = 5.5) and cationic polymer (PLR or PEI)-to-polynucleotide plus anionic polymer molar ratios of 5.5:1 and 10:1 (as shown in the bars labeled n/(p+2c) = 5.5 or 10), with or without addition of HTP. Addition of PDGA did not impair complexation kinetics at any of the molar ratios tested.
[0044] Effects of including a cationic polymer and cationic polypeptide on polyplex destabilization were also determined, as shown in FIG. 5. Polyplex nanoparticles of DNA and cationic polypeptides (PLR with or without HTP, or PEI with HTP) with [(PDGA) carboxylate(c):(DNA) phosphate(p)] molar ratios varying from 0 to 100 were complexed as described, compared to DNA or EtBr alone as controls, and the effects of destabilization (as indicated by increased fluorescence) was determined. In the absence of HTP, addition of PDGA did not lead to polyplex destabilization.

However, in the presence of HTP, adding molar ratios of PDGA to DNA of 20 and above led to polyplex destabilization. These results indicate a surprising synergistic effect of cationic polypeptide and anionic polymer on complex destabilization.

Cationic polypeptide incorporation, and/or inclusion of cationic constituents of disparate molecular weights or sizes, into a nanoparticle polyplex core may beneficially enhance the ability of a cationic polymer to promote dissociation and release of the polynucleotide payload from the polyplex and its other constituents.
[0045] Dynamic light scattering (BRAND) was used to determine the hydrodynamic radii of nanoparticles at various stages of formation.
Nanoparticles containing core polyplexes with plasmid DNA, PLR, PDGA, and HTP, at a molar ratio of [amide]:[(phosphate)] of 5.5:1 were complexed as described. Some polyplex cores were further coated with silica as described. And some silica-coated polyplexes were further layered with cationic polymer (SEQ ID NO: 4) as described. 30 ¨

minutes of measurements were obtained following initial core formation of ternary complexes, silica coating of cores, and cationic polymer-coating of silica-coated cores. FIG. 6 is a graph showing diameters of nanoparticles. Uncoated polyplex cores and polyplex cores coated with silica were approximately 70-150 nm in diameter on average. In other embodiments, polyplex cores and silica-coated polyplex cores may be within a range of 100-170 nm in average diameter. Adding a cationic polymer coating to the silica coating yielded a nanoparticle with an average diameter of approximately 170 nm. In other embodiments, silica-coated polyplex cores with an additional layer of cationic polymer attached to the outer layer of silica may be within a range of approximately 80-200 nm in average diameter.
[0046] Cellular uptake of nanoparticles was also determined. Fluorescein isothiocyanate (FITC) was covalently conjugated to amines of PEI (25 kDa linear) and PLR (29 kDa) such that the molar ratio of amines to FITC was 100:1. The reaction was performed in darkness at room temperature for four hours in equal volumes of water and DMSO. In order to establish conjugation, a 0.05% w/v 500 uL
solution of each fluorescently modified polymer was centrifuged in a 10 kDa Nanosep0 filter and the eluate's fluorescence intensity (485 ex./520 em.) was compared to the unfiltered polymer solution as well as water. mCherry plasmid (Addgene) was included in nanoparticles to permit fluorescent detection of plasmid-driven expression.
[0047] MC3T3 murine osteoblasts were cultured on polystyrene T-75 tissue culture plastic flasks (Corning, CA, USA). Dulbecco's modified eagle medium supplemented with 10% Fetal Bovine Serum (Thermo Fisher Scientific, VA, USA) was used for osteoblasts along with 1% penicillin/streptomycin (Invitrogen, NY, USA). Xylenol orange was added to the cell culture media from day 15 to day 25 after initiation of cell culture. At day 25 cells were fixed and assayed for mineralization. For mCherry plasmid delivery using FITC -modified nanoparticles, osteoblasts were plated at 1000 cells/well in 96-well plates and allowed to adhere for 12 - 16 hours in antibiotic-free DMEM containing 10% FBS. Immediately before transfection, medium was replaced with equal volumes of OptiMEM-suspended nanoparticles and DMEM containing 10% FBS.
[0048] All complexes were FITC-labeled and subjected to qualitative observation of fluorescence intensity (488/520 ex./em.) before transfection. 96-well-plated osteoblasts (1000 cells/well) were transfected with 200 ng of plasmids in triplicates for each binary (plasmid and cationic polymer), ternary (plasmid and cationic polymer, plus anionic polymer or cationic polypeptide), and quaternary (plasmid, cationic polymer, anionic polymer, and cationic polypeptide) complex as well as its silica-coated counterpart, with 1 control and 8 experimental sets (n = 3) in total. 5%
serum was used in order to study effects of serum on extracellular properties of aggregation.
[0049] At 30-hours post-transfection, bimodal fluorescent imaging allowed for simultaneous observation of FITC-labeled nanoparticles (488 ex./520 em.) and the mCherry gene expression that they were responsible for (633 ex./680 em.). A
minimum of 20 cells were observed at different locations in each well and representative images were obtained. ImageJ was used to process the overlaid images and combine phase-contrast, 488/520 and 633/680 channels.
[0050] Photomicrographs demonstrating cellular uptake are shown in FIG. 7.
Circles in FIG. 7 indicate where high levels of nuclear localization is apparent. Silica-coated binary nanoparticles show burst release properties (i.e., nuclear localization is not apparent in the DNA-PLR + silica samples). Inclusion of PDGA in polyplex cores causes prolonged release of plasmid within cell nuclei. This effect of PDGA to cause prolonged release was surprising in light of literature suggesting the opposite:

that including cationic polymers in nanoparticle polyplexes would hasten, and shorten the duration of, dissociation of polynucleotide payload from other polyplex constituents. Addition of HTP also causes extensive nuclear localization.
[0051] Further coating of silica-coated nanoparticles (DNA-HTP-PDGA-PLR + Si) with poly(arginine) (SEQ ID NO: 4) causes nanoparticles to be stable in serum and causes extended residence of nanoparticle payload within cells. FIG. 8. is photomicrographs showing cellular uptake and retention of silica-coated FITC-conjugated polyplex cores, to which an additional layer of poly(L-arginine) (SEQ ID
NO: 4) has been added, by MC3T3 murine osteoblasts, in accordance with the present invention. Unlike for silica-coated nanoparticles shown in FIG. 7, no aggregation of nanoparticles containing an additional layer of cationic polymers on the outside of the silica coating is observable in FIG. 8, indicating that such nanoparticles remain stable in serum. Furthermore, these nanoparticles are observed to display extended residence within the cell nucleus such that fluorescence qualitatively peaks within approximately 1.5 days and detectable fluorescence was sustained through 14 days.
[0052] Layering silica-coated polyplex cores with polymers specifically directed to bind to particular cell types can further enhance uptake. Associating ligands for cellular receptors with the surface of a nanoparticle can enhance affinity of the nanoparticle for cells that express such receptors and increase transfection of such cells. As one example in accordance with the present invention, silica-coated polyplexes were coated with VEGF (SEQ ID NO: 5), a high-affinity ligand for VEGF
receptors, which are expressed at high levels by human umbilical vein endothelial cells (HUVECs). HUVECs were incubated with silica-coated FITC-conjugated polyplexes with poly(L-arginine) (SEQ ID NO: 4) or human VEGF (SEQ ID NO: 5) attached to the outer surface of the silica coating for 40 min before being washed twice with PBS then resuspended in DMEM (10% FBS). Cells were imaged 4 hrs later. After this short incubation period, only low levels of transfection with nanoparticles containing a poly(L-arginine) layer attached to the external silica surface (FIG. 9A) was observed, whereas coating with VEGF instead of poly(L-arginine) resulted in significantly greater cellular internalization at this four-hour time point. A skilled artisan would recognize that virtually any other cell type may also be transfected by nanoparticles in accordance with the present invention, and that a layer of polymers may be attached to the outer layer of silica-coated polyplex cores to promote or otherwise influence this effect. Such a person would also comprehend that other means of contacting cells with nanoparticles to effect such outcomes, such as i.p., i.v., i.m. or s.c. or other injection or transdermal administration or via suppository to, or ingestion or oral or nasal inhalation by, a human or animal, or contact with explanted tissue or cells or stem cells, would also be included within the present invention.
[0053] In another aspect of the invention, a polynucleotide encoding a nuclease may be incorporated into the nanoparticle polyplex core. As one nonlimiting example, a polynucleotide that encodes and drives expression of a TALEN (Transcription Factor-Like Effector Nucleases) may be included in the nanoparticle. Like Zinc Finger Nucleases, TALENs utilize a modular DNA binding motif (TALE) that can be modified to introduce new DNA binding specificities and even nucleases (TALEN).
TALEs consist of multiple repeat variable diresidues (RVDs) which each specify binding to a single nucleotide. TALE arrays are made by stringing together RVDs in a specific order to provide specificity and binding affinity to desired DNA
sequences.
Commonly, these genome-splicing tools are engineered by fusing non-specific cleavage domains, such as FokI nucleases, to TALEs. TALEN assembly protocols are available that allow assembly of these repetitive sequences, including an open source assembly method known as Golden Gate.
[0054] In another aspect of the present invention, nanoparticles may be designed and used in a manner to regulate expression of signaling molecules to alter cellular function. For example, sequences of chromosomal DNA may be deleted or altered to generate cellular or animal models of disease states or treatments therefor, or to treat disease states or otherwise enhance human health. One nonlimiting example of a protein whose expression may be modified in accordance with the present invention is sclerostin (SOST). SOST binding to the LRP5/6 receptor inhibits Wnt signaling, perhaps via feedback systems between Wnt3A, Wnt7B, Wntl OA, sclerostin, 13-catenin, LEF1, and TCF1. Desuppressing these cascades via removal of sclerostin may result in significantly increased mineralization activity.
[0055] Osteoprogenitor (OPG) and RANKL are also expected to play a responsive role to SOST deletion, where RANKL expresses itself as a receptor for promoting osteoclastogenesis via osteoclast-linked RANK or ODF (osteoclast differentiation factor) binding, and OPG binds antagonistically to RANKL. Thus, the ratio between OPG and RANKL is a determinant of the relationship between bone formation and resorption. However, single cultures of osteoblasts will communicate through other forms of paracrine signaling and this ratio should be more reflective of behavior of altered cells in co-culture with osteoclasts or in vivo.
[0056] In another aspect of the present invention, a nanoparticle may be designed so as to allow transfection with a TALEN that may disrupt expression of SOST and consequently generate a high bone-mass phenotype. As one example, TALENS may be engineered to specifically bind to loci in the SOST gene and create double-stranded breaks in the genome to disrupt transcription or translation and reduce SOST
expression. As a further example, a nanoparticle may contain plasmids that encode two TALENs that create double-stranded breaks on either side of the chromosomal locus of the start codon for SOST. Repair of endogenous genomic DNA following excision of the sequence encoding the start codon may result in transcription of sclerostin mRNA lacking the start codon that cannot be properly translated into SOST
protein, thereby driving down SOST expression and activity. A diagrammatic representation of this model is shown in FIG. 10, where a "left" TALEN and "right"
TALEN bind to and cleave sites on opposite sides of the SOST start codon locus. As one example, a left TALEN may have the sequence represented by SEQ ID NO: 6, and a right TALEN may have the sequence represented by SEQ ID NO: 7. A
nanoparticle may comprise an expression plasmid, such as pUC19 (Genbank Accession Number L09137 X02514), into which a nucleotide sequence that encodes a right or left TALEN, such as those represented by SEQ ID NO: 6 and SEQ ID NO:
7, has been subcloned so as to drive cellular expression of the encoded TALEN. A
nanoparticle may also include combinations of expression plasmids that comprise sequences that encode left and right TALENs.
[0057] A nanoparticle may also comprise other TALEN sequences, targeting SOST
or any other gene of interest, and also may comprise other expression vectors, in accordance with the present invention. A nanoparticle may comprise other types of polynucleotides or analogs thereof, such as species of RNA or DNA including mRNA, siRNA, miRNA, aptamers, shRNA, AAV-derived nucleic acids, morpholeno RNA, peptoid and peptide nucleic acids, cDNA, DNA origami, DNA and RNA with synthetic nucleotides, DNA and RNA with predefined secondary structures, CRISPR
sequences, and multimers and oligomers, and any combination of the foregoing, in accordance with the present invention. In another example, a nanoparticle may comprise polynucleotides whose sequence may encode other products such as any protein or polypeptide whose expression is desired. A skilled artisan would recognize that the foregoing examples are in accordance with the present invention and may be encompassed by claims thereto.
[0058] Following transfection of MC3T3 murine osteoblasts with nanoparticles designed to knock down SOST expression in accordance with the present invention, ELISA and quantitative real-time PCR (qPCR) assays were performed on cell lysate and supernatant fractions. FIGs. 11A-11C are graphs demonstrating the effectiveness of different amounts (800 ng, 1600 ng, or 2500 ng) of nanoparticles (NP) containing expression plasmids comprising nucleotide sequences that encode left (SEQ ID
NO:
6) and right (SEQ ID NO: 7) SOST TALENs, in accordance with the present invention, in modulating SOST expression and I3-catenin expression over a period of up to over 20 days following transfection. For comparison, other cells were transfected with mRNA encoding the same TALENS using Lipofectamine, a known agent for cellular transfection. As shown in FIGs. 11A-11C, intracellular and extracellular SOST levels were suppressed for at least several weeks following transfection with nanoparticles in accordance with the present invention, whereas 13-catenin expression was concomitantly up-regulated, signifying effectiveness of the nanoparticles in downregulating SOST expression and activity.
[0059] qPCR was also performed to determine whether down-regulation of SOST
expression with nanoparticles in accordance with the present invention may have downstream effects on other components of the relevant signaling cascade.
Cells were transfected as described above. Results on expression of numerous components of the signaling pathway (SOST, I3-catenin, TCF1, LEF1, Wnt3A, Wnt7B, Wntl0b, OPG, and RANKL), at 5, 14, and 21 days after transfection with different amounts of nanoparticles as indicated, are shown in FIGs. 12A-12F. For comparison, other cells were transfected with mRNA encoding the same TALENS using Lipofectamine. The real time PCR results showed a greater up regulation of Wnt responsive genes in the cell lines transfected with nanoparticles delivering SOST TALENS as compared to the SOST TALENS delivered by Lipofectamine by up to 2 to 6 times as a response to knockdown of the Wnt signaling inhibitor sclerostin.
[0060] TCF/LEF-1-mediated transcription may also be upregulated following knockdown of SOST expression in accordance with the present invention. MC3T3-El cells were transfected with TOPflash and control FOPflash luciferase reporter plasmid constructs (Addgene# 12456 and 12457) that contain TCF/LEF-1 binding sites. The cells were plated at the density of 5000 cells/well of the 8-well labtek chamber slides and transfected with 1 ug of TOPflash and FOPflash plasmid separately. To control for the efficiency of transfection a control plasmid Renilla (Promega) was used. FIG 13 is photomicrographs showing upregulation of TCF/LEF-1-mediated transcription for 21 days following tranfection with nanoparticles containing plasmids encoding SOST-directed TALENS, in accordance with the present invention, consistent with an upregulation of TCF/LEF-1 expression and activity following transfection with the invented nanoparticles.
[0061] Knockdown of SOST expression in accordance with the present invention may also increase mineralization in stromal bone marrow cells and osteoblasts.

Mineralization was quantified by two separate methods, first based on image thresholding of xylenol-orange-labeled vital cultures using MATLAB (Mathworks, Natick, MA), and second by atomic absorption spectroscopy (AAS). For the xylenol orange threshold, images of both phase and fluorescence (with Texas Red Filter Set) were taken in five adjacent regions of wells, and then stitched into a larger 8-bit image (4x, Nikon Ti-100). The phase channel was subtracted from the fluorescence, and a threshold was set to half the level between the background and signal (-6dB).
The number of pixels above the threshold were counted and used to express the percentage of mineralized area in each well. The combination of phase and fluorescence allowed for unbound xylenol orange to be distinguished, whereas the use of decibel levels allowed for correction of the varied background levels in each image.
[0062] Mineralization was also quantified by atomic absorption with an atomic absorption spectrometer (AA-Perkin Elmer, MA). Each well was prepared by adding 0.5 mL of 10% nitric acid, and the resultant calcium content was measured relative to a standard curve and compared between groups. Care was taken to minimize interference due to ionized calcium precipitating with phosphate phases, so a large excess of potassium and lanthanum ions was added to each well.
[0063] FIGs 14A-14C show the effects of transfection with nanoparticles in accordance with the present invention on mineralization following SOST
knockdown.
FIG. 14A is photomicrographs of staining of the mineralized matrix formed 25 days after SOST knockdown. Stromal cells are shown in panels A-C, wherein panel A
show control cells, panel B shows cells transfected via Lipofectamine, and panel C
shows cells transfected with nanoparticles containing plasmids encoding SOST-directed TALENs as described and in accordance with the present invention.
MC3T3-E1 osteoblast cells are shown in panels D-G, wherein panel D show control cells, and panels E-G show cells transfected with nanoparticles containing plasmids encoding SOST-directed TALENs as described at doses of 800 ng, 1600 ng, and ng, respectively, in accordance with the present invention. FIGs. 14B and 14C
are graphs showing quantification of mineralization. FIGs 14A-C demonstrate increased calcium concentration in stromal bone marrow cells and osteoblasts following transfection with SOST-targetting TALENS via nanoparticles in accordance with the present invention, further confirming the effectiveness of this technique of modifying the cellular expression and activity of genes and downstream signaling pathways.
[0064] While several aspects of the present invention have been described and depicted herein, alternative aspects may be effected by those skilled in the art to accomplish the same objectives. Accordingly, it is intended by the appended claims to cover all such alternative aspects as fall within the true spirit and scope of the invention.

Claims (24)

1. A nanoparticle comprising:
a core polyplex and a silica coating thereon;
wherein said core polyplex comprises an anionic polymer, a cationic polymer, a cationic polypeptide, and a polynucleotide.
2. The nanoparticle of claim 1 wherein the anionic polymer is poly(D-glutamic acid).
3. The nanoparticle of claim 1 wherein the cationic polymer is selected from the group consisting of poly(ethylenimine) and poly(L-arginine).
4. The nanoparticle of claim 1 wherein the cationic polypeptide is a histone tail peptide.
5. The nanoparticle of claim 4 wherein the histone tail peptide is human H3 histone tail peptide.
6. The nanoparticle of claim 1 wherein the anionic polymer is poly(D-glutamic acid), the cationic polymer is selected from the group consisting of poly(ethylenimine) and poly(L-arginine), and the cationic polypeptide is a histone tail peptide.
7. The nanoparticle of claim 6 wherein the polynucleotide comprises a nucleotide sequence that encodes a nuclease.
8. The nanoparticle of claim 7 wherein the nuclease is a TALEN.
9. The nanoparticle of claim 8 wherein the TALEN is capable of inducing a break at a site-specific locus of DNA, wherein the break results in a change of expression of a protein encoded by a gene.
10. The nanoparticle of claim 9 wherein the change is a decrease and the gene encodes a sclerostin protein.
11. A nanoparticle of claim 6, further comprising a polymer attached to an outer surface of said silica coating.
12. A nanoparticle of claim 11, wherein said polymer attached to an outer surface of said silica coating comprises poly(L-arginine) or a vasoactive endothelial growth factor peptide.
13. A method of modifying intracellular polynucleotides comprising;
contacting a cell with a nanoparticle, wherein said nanoparticle comprises a core polyplex and a silica coating thereon;
wherein said core polyplex comprises an anionic polymer, a cationic polymer, a cationic polypeptide, and a polynucleotide.
14. The method of claim 13 wherein the anionic polymer is poly(D-glutamic acid).
15. The method of claim 13 wherein the cationic polymer is selected from the group consisting of poly(ethylenimine) and poly(L-arginine).
16. The method of claim 13 wherein the cationic polypeptide is a histone tail peptide.
17. The method of claim 16 wherein the histone tail peptide is human H3 histone tail peptide.
18. The method of claim 13 wherein the anionic polymer is poly(D-glutamic acid), the cationic polymer is selected from the group consisting of poly(ethylenimine) and poly(L-arginine), and the cationic polypeptide is a histone tail peptide.
19. The method of claim 18 wherein the polynucleotide comprises a nucleotide sequence that encodes a nuclease.
20. The method of claim 19 wherein the nuclease is a TALEN.
21. The method of claim 20 wherein the TALEN is capable of inducing a break at a site-specific locus of DNA, wherein the break results in a change of expression of a protein encoded by a gene.
22. The nanoparticle of claim 21 wherein the change is a decrease and the gene encodes a sclerostin protein.
23. A nanoparticle of claim 18, further comprising a polymer attached to an outer surface of said silica coating.
24. A nanoparticle of claim 23, wherein said polymer attached to an outer surface of said silica coating comprises poly(L-arginine) or a vasoactive endothelial growth factor peptide.
CA2924535A 2013-09-23 2014-09-23 Nanoparticle-mediated gene delivery, genomic editing and ligand-targete d modification in various cell populations Active CA2924535C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3175320A CA3175320A1 (en) 2013-09-23 2014-09-23 Nanoparticle-mediated gene delivery, genomic editing and ligand-targeted modification in various cell populations

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361881072P 2013-09-23 2013-09-23
US61/881,072 2013-09-23
PCT/US2014/057000 WO2015042585A1 (en) 2013-09-23 2014-09-23 Nanoparticle-mediated gene delivery, genomic editing and ligand-targeted modification in various cell populations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3175320A Division CA3175320A1 (en) 2013-09-23 2014-09-23 Nanoparticle-mediated gene delivery, genomic editing and ligand-targeted modification in various cell populations

Publications (2)

Publication Number Publication Date
CA2924535A1 true CA2924535A1 (en) 2015-03-26
CA2924535C CA2924535C (en) 2022-12-13

Family

ID=52689537

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2924535A Active CA2924535C (en) 2013-09-23 2014-09-23 Nanoparticle-mediated gene delivery, genomic editing and ligand-targete d modification in various cell populations
CA3175320A Pending CA3175320A1 (en) 2013-09-23 2014-09-23 Nanoparticle-mediated gene delivery, genomic editing and ligand-targeted modification in various cell populations

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3175320A Pending CA3175320A1 (en) 2013-09-23 2014-09-23 Nanoparticle-mediated gene delivery, genomic editing and ligand-targeted modification in various cell populations

Country Status (12)

Country Link
US (2) US10526616B2 (en)
EP (2) EP3049116B1 (en)
JP (1) JP6595459B2 (en)
KR (1) KR20160060133A (en)
CN (1) CN105579068A (en)
AU (1) AU2014321215B2 (en)
CA (2) CA2924535C (en)
ES (1) ES2719112T3 (en)
IL (1) IL244585B (en)
PT (1) PT3049116T (en)
RU (1) RU2670512C2 (en)
WO (1) WO2015042585A1 (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6261500B2 (en) 2011-07-22 2018-01-17 プレジデント アンド フェローズ オブ ハーバード カレッジ Evaluation and improvement of nuclease cleavage specificity
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
JP7109784B2 (en) 2015-10-23 2022-08-01 プレジデント アンド フェローズ オブ ハーバード カレッジ Evolved Cas9 protein for gene editing
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
KR102547316B1 (en) 2016-08-03 2023-06-23 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Adenosine nucleobase editing agents and uses thereof
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
EP3526320A1 (en) 2016-10-14 2019-08-21 President and Fellows of Harvard College Aav delivery of nucleobase editors
CN110582301A (en) * 2016-12-14 2019-12-17 利甘达尔股份有限公司 Methods and compositions for nucleic acid and protein payload delivery
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
JP7348063B2 (en) 2017-01-05 2023-09-20 フレッド ハッチンソン キャンサー センター Systems and methods for improving vaccine efficacy
JP2020510038A (en) 2017-03-09 2020-04-02 プレジデント アンド フェローズ オブ ハーバード カレッジ Cancer vaccine
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
JP2020510439A (en) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ Base-editing factor from cytosine to guanine
CA3057192A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
WO2019023680A1 (en) 2017-07-28 2019-01-31 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
KR20250107288A (en) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 Uses of adenosine base editors
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
CN111629715A (en) 2018-01-18 2020-09-04 弗莱德哈钦森癌症研究中心 Altering inflammatory states of immune cells in vivo by modulating cell activation state
US20210148918A1 (en) * 2018-04-17 2021-05-20 Purdue Research Foundation Modifying surface of a live cell and the uses thereof
AU2019255725A1 (en) * 2018-04-18 2020-12-10 Ligandal, Inc. Methods and compositions for genome editing
EP3796894A4 (en) * 2018-04-24 2022-05-04 Ligandal, Inc. METHODS AND COMPOSITIONS FOR GENOME EDITING
SG11202010631UA (en) * 2018-04-27 2020-11-27 Genedit Inc Cationic polymer and use for biomolecule delivery
EP3797160A1 (en) 2018-05-23 2021-03-31 The Broad Institute Inc. Base editors and uses thereof
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
WO2020028319A1 (en) * 2018-07-30 2020-02-06 Sinica, Academia Therapeutic nanoparticles by coacervate complexation and their use for treating bacteria
JP2022502384A (en) 2018-09-25 2022-01-11 国立大学法人 東京大学 An amphipathic polyamino acid, a block copolymer using the amphipathic polyamino acid, and a complex containing the amphipathic polyamino acid or the block copolymer and nucleic acid.
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
WO2020117706A1 (en) 2018-12-03 2020-06-11 Triplet Therapeutics, Inc. Methods for the treatment of trinucleotide repeat expansion disorders associated with mlh3 activity
US20220056455A1 (en) 2018-12-20 2022-02-24 Praxis Precision Medicines, Inc. Compositions and methods for the treatment of kcnt1 related disorders
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
JP7657726B2 (en) 2019-03-19 2025-04-07 ザ ブロード インスティテュート，インコーポレーテッド Editing Methods and compositions for editing nucleotide sequences
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US20220296683A1 (en) * 2019-09-20 2022-09-22 University College Dublin Oral delivery system
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
DE112021002672T5 (en) 2020-05-08 2023-04-13 President And Fellows Of Harvard College METHODS AND COMPOSITIONS FOR EDIT BOTH STRANDS SIMULTANEOUSLY OF A DOUBLE STRANDED NUCLEOTIDE TARGET SEQUENCE
WO2021231679A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
WO2021231692A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of otoferlin (otof)
WO2021231673A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
WO2021231685A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
EP4150078A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
WO2021231675A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
EP4150089A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of retinoschisin 1 (rs1)
WO2021231680A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
AR122534A1 (en) 2020-06-03 2022-09-21 Triplet Therapeutics Inc METHODS FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY
EP4341405A1 (en) 2021-05-20 2024-03-27 Korro Bio, Inc. Methods and compositions for adar-mediated editing
WO2022256283A2 (en) 2021-06-01 2022-12-08 Korro Bio, Inc. Methods for restoring protein function using adar
WO2023278410A1 (en) 2021-06-29 2023-01-05 Korro Bio, Inc. Methods and compositions for adar-mediated editing
US20230194709A9 (en) 2021-06-29 2023-06-22 Seagate Technology Llc Range information detection using coherent pulse sets with selected waveform characteristics
US20250352667A1 (en) 2021-10-22 2025-11-20 Korro Bio, Inc. Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
MX2024007790A (en) 2021-12-22 2024-09-06 Camp4 Therapeutics Corp MODULATION OF GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS.
EP4536831A2 (en) 2022-06-10 2025-04-16 Camp4 Therapeutics Corporation Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas
AU2023403208A1 (en) 2022-12-01 2025-06-19 Camp4 Therapeutics Corporation Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas
WO2025015338A1 (en) 2023-07-13 2025-01-16 Korro Bio, Inc. Rna-editing oligonucleotides and uses thereof
AU2024287308A1 (en) 2023-07-13 2025-12-18 Korro Bio, Inc. Rna-editing oligonucleotides and uses thereof
WO2025128799A1 (en) 2023-12-12 2025-06-19 Korro Bio, Inc. Double-stranded rna-editing oligonucleotides and uses thereof
WO2025255388A1 (en) 2024-06-05 2025-12-11 Camp4 Therapeutics Corporation Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US6379966B2 (en) 1999-02-26 2002-04-30 Mirus Corporation Intravascular delivery of non-viral nucleic acid
US7098032B2 (en) * 2001-01-02 2006-08-29 Mirus Bio Corporation Compositions and methods for drug delivery using pH sensitive molecules
RU2295954C2 (en) * 2000-09-28 2007-03-27 Чирон Корпорейшн Microparticles for delivery of heterologous nucleic acids
US20040102606A1 (en) 2001-04-24 2004-05-27 Danuta Balicki Histone H2A -derived peptides useful in gene delivery
US6805904B2 (en) 2002-02-20 2004-10-19 International Business Machines Corporation Process of forming a multilayer nanoparticle-containing thin film self-assembly
US7524630B2 (en) * 2002-04-22 2009-04-28 University Of Florida Research Foundation, Inc. Functionalized nanoparticles and methods of use
US20070026069A1 (en) 2003-03-28 2007-02-01 Shastri Venkatram P Biommetic hierarchies using functionalized nanoparticles as building blocks
EP1660053A2 (en) 2003-08-21 2006-05-31 Southwest Research Institute Skeletally targeted nanoparticles
US20070190155A1 (en) 2004-03-05 2007-08-16 Leary James F Molecular programming of nanoparticle systems for an ordered and controlled sequence of events for gene-drug delivery
WO2005123142A1 (en) 2004-06-10 2005-12-29 Abraxis Bioscience, Inc. A method using inorganic nanoparticles as non-viral vectors for gene therapy
US20060088599A1 (en) 2004-08-02 2006-04-27 Prasad Paras N Amino functionalized ORMOSIL nanoparticles as delivery vehicles
US20100015218A1 (en) 2007-02-16 2010-01-21 Vasant Jadhav Compositions and methods for potentiated activity of biologically active molecules
WO2008109806A2 (en) 2007-03-08 2008-09-12 Massachusetts Institute Of Technology Electrostatic coating of particles for drug delivery
JP2011517279A (en) 2007-10-29 2011-06-02 ユニバーシティ オブ マサチューセッツ Yeast cell wall particles (YCWP) multi-layered nanoparticles for nucleic acid (siRNA) delivery
US8323618B2 (en) 2007-11-07 2012-12-04 University Of Houston System Ultrasmall superparamagnetic iron oxide nanoparticles and uses thereof
WO2009061515A1 (en) 2007-11-09 2009-05-14 Northeastern University Self-assembling micelle-like nanoparticles for systemic gene delivery
US7999025B2 (en) 2008-01-28 2011-08-16 University Of Utah Research Foundation Asymmetrically-functionalized nanoparticles organized on one-dimensional chains
US8324333B2 (en) 2008-06-05 2012-12-04 Wisconsin Alumni Research Foundation Anionic charge-dynamic polymers for release of cationic agents
AR076225A1 (en) 2009-04-07 2011-05-26 Dow Agrosciences Llc ADMINISTRATION OF NANOPARTICLES COVERED BY A SEQUENCE OF SPECIFIC NUCLEASE
HUE041436T2 (en) * 2009-12-10 2019-05-28 Univ Minnesota Tal-effector-mediated DNA modification
WO2011096408A1 (en) 2010-02-02 2011-08-11 国立大学法人 東京大学 Fine composite particles and method of producing same, and pharmaceutical composition using fine composite particles
US9074187B2 (en) 2011-03-21 2015-07-07 Board Of Trustees Of The University Of Arkansas Nanostructural materials that increase mineralization in bone cells and affect gene expression through miRNA regulation and applications of same
EP2694089B1 (en) * 2011-04-05 2024-06-05 Cellectis New tale-protein scaffolds and uses thereof
US8450107B1 (en) 2011-11-30 2013-05-28 The Broad Institute Inc. Nucleotide-specific recognition sequences for designer TAL effectors
KR102177557B1 (en) 2012-06-20 2020-11-11 유니버시티 오브 워터루 Mucoadhesive nanoparticle delivery system
EP2931899A1 (en) 2012-12-12 2015-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof

Also Published As

Publication number Publication date
EP3049116A4 (en) 2017-05-17
RU2016115721A3 (en) 2018-03-21
JP6595459B2 (en) 2019-10-23
CA3175320A1 (en) 2015-03-26
EP3520822A1 (en) 2019-08-07
ES2719112T3 (en) 2019-07-08
US20160230189A1 (en) 2016-08-11
PT3049116T (en) 2019-04-03
IL244585B (en) 2019-11-28
JP2016533322A (en) 2016-10-27
KR20160060133A (en) 2016-05-27
IL244585A0 (en) 2016-04-21
CA2924535C (en) 2022-12-13
RU2016115721A (en) 2017-10-30
CN105579068A (en) 2016-05-11
AU2014321215B2 (en) 2020-07-16
WO2015042585A1 (en) 2015-03-26
EP3049116B1 (en) 2019-01-02
US20200181642A1 (en) 2020-06-11
AU2014321215A1 (en) 2016-04-21
EP3049116A1 (en) 2016-08-03
US10526616B2 (en) 2020-01-07
RU2670512C2 (en) 2018-10-23

Similar Documents

Publication Publication Date Title
US20200181642A1 (en) Nanoparticle-mediated gene delivery, genomic editing and ligand-targeted modification in various cell populations
Levingstone et al. Calcium phosphate nanoparticles-based systems for RNAi delivery: Applications in bone tissue regeneration
JP6768664B2 (en) Peptides and nanoparticles for intracellular delivery of molecules
Margus et al. Cell-penetrating peptides as versatile vehicles for oligonucleotide delivery
Tagalakis et al. Multifunctional, self-assembling anionic peptide-lipid nanocomplexes for targeted siRNA delivery
Kim et al. RNA interference in vitro and in vivo using an arginine peptide/siRNA complex system
KR20240172763A (en) Compositions and methods for nucleic acid and/or protein payload delivery
Gu et al. Current understanding and translational prospects of tetrahedral framework nucleic acids
Zuris et al. Efficient delivery of genome-editing proteins in vitro and in vivo
CN112584873B (en) Peptides used as cell penetrating peptides
Liu et al. Delivery of miRNA‐29b using R9‐LK15, a novel cell‐penetrating peptide, promotes osteogenic differentiation of bone mesenchymal stem cells
KR20210038841A (en) Methods and compositions for genome editing
Jiang et al. Postfunctionalization of noncationic RNA–polymer complexes for RNA delivery
Mozley et al. A mechanistic dissection of polyethylenimine mediated transfection of CHO cells: To enhance the efficiency of recombinant DNA utilization
HK1225274B (en) Nanoparticle-mediated gene delivery, genomic editing and ligand-targeted modification in various cell populations
HK1225274A1 (en) Nanoparticle-mediated gene delivery, genomic editing and ligand-targeted modification in various cell populations
Ren et al. Self-Assembled Plasmid Delivery System for PPM1D Knockout to Reverse Tumor Malignancy
Jun et al. Design of a multicomponent peptide-woven nanocomplex for delivery of siRNA
Shen Understanding the Biological Barriers to Jurkat Transfection using Non-Viral Peptides
Watanabe et al. Intracellular delivery of RNA via RNA-binding proteins or peptides
Pärnaste How, why, what and where: Mechanisms behind CPP/cargo nanocomplexes
Nelles Recognizing and Utilizing Cellular RNA Content with CRISPR, Nanoparticles, and Synthetic Polymers
HK1245305B (en) Peptides and nanoparticles for intracellular delivery of molecules
HK1245305A1 (en) Peptides and nanoparticles for intracellular delivery of molecules

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190826

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250321

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250321

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260319

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260319